Bendamustine and Bevacizumab for Advanced Cancers

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT01152203
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
13 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bendamustine — DRUG
    Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle
  • Bevacizumab — DRUG
    10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle

Study Details

The goal of this clinical research study is to find the highest tolerable combination dose of bendamustine and bevacizumab that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.

Key Dates

First listed
Jun 29, 2010
Start date
Jun 30, 2010
Status verified
May 2014
Primary completion
May 31, 2014
Completion
May 31, 2014

Study Design

Enrollment
59 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bendamustine + Bevacizumab
    Bendamustine starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle. Bevacizumab 10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle.

Primary Outcome Measure

Maximum Tolerated Dose (MTD) of Bendamustine and Bevacizumab [ Time Frame: 28 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
UT MD Anderson Cancer Center· Houston, TX

Related Studies